SCHEMBL4926246

SCHEMBL4926246

O=C(NCCc1cccs1)Nc1cccc(Cl)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.64
KMT2A Q03164 7/20 0.64
MAPT P10636 5/20 0.64
NPC1 O15118 5/20 0.64
RAB9A P51151 5/20 0.64
LMNA P02545 4/20 0.64
HTT P42858 3/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
NPSR1 Q6W5P4 1/20 0.62
ALDH1A1 P00352 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
TP53 P04637 1/20 0.58
HPGD P15428 1/20 0.58
EPHX1 P07099 3/20 0.57
TAAR1 Q96RJ0 1/20 0.55
CASR P41180 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922221 0.85 NPC1 (0.75) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL14433947 0.85 HPGD (0.77) MEN1KMT2AMAPTRAB9ALMNA
SCHEMBL4918510 0.84 MEN1 (0.62) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL4917108 0.84 CA12 (0.65) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL4920567 0.82 KMT2A (0.64) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL14465082 0.82 CA12 (0.58) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL15203319 0.79 MEN1 (0.68) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL28414184 0.79 KMT2A (1.00) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL27941643 0.78 EPHX1 (0.70) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6687855 0.78 MEN1 (0.69) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MEN1 4843/4885KMT2A 1905/4885MAPT 4151/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MEN1 4843/4885KMT2A 1905/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.